---
title: Certoparin
description: >-
  - Certoparin is prescribed for the prevention and treatment of venous
  thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary
  embolism (PE). It is also used in other medical settings where there is a risk
  of blood clot formation such as post-surgery and in acutely ill hospi...
is_banned: false
lastModified: '2025-09-22T17:21:52.547Z'
faqs:
  - q: >-
      What is the recommended dosage for Certoparin?**


      **A:**  The dosage varies according to the clinical indication. See
      detailed dosing information above.
    a: >-
      A:**  The dosage varies according to the clinical indication. See detailed
      dosing information above.
  - q: |-
      How is Certoparin administered?**

      **A:** Subcutaneous injection.
    a: 'A:** Subcutaneous injection.'
  - q: |-
      What are the key side effects to watch for?**

      **A:**  Bleeding, bruising, thrombocytopenia, allergic reactions.
    a: 'A:**  Bleeding, bruising, thrombocytopenia, allergic reactions.'
  - q: >-
      What are the contraindications to Certoparin use?**


      **A:** Active major bleeding, severe thrombocytopenia, hypersensitivity to
      certoparin or heparin.
    a: >-
      A:** Active major bleeding, severe thrombocytopenia, hypersensitivity to
      certoparin or heparin.
  - q: >-
      Can Certoparin be used in pregnancy?**


      **A:** Yes, it has been shown to be safe and effective in preventing VTE
      during pregnancy. It does not cross the placenta. Monitor coagulation
      parameters and pregnancy complications.
    a: >-
      A:** Yes, it has been shown to be safe and effective in preventing VTE
      during pregnancy. It does not cross the placenta. Monitor coagulation
      parameters and pregnancy complications.
  - q: >-
      Is Certoparin safe during breastfeeding?**


      **A:**  Yes, it is not secreted in clinically significant amounts into
      breast milk.
    a: >-
      A:**  Yes, it is not secreted in clinically significant amounts into
      breast milk.
  - q: >-
      How does Certoparin interact with other anticoagulants?**


      **A:**  Increases the risk of bleeding.  Close monitoring is needed when
      used concomitantly.
    a: >-
      A:**  Increases the risk of bleeding.  Close monitoring is needed when
      used concomitantly.
  - q: >-
      What should be monitored in patients receiving Certoparin?**


      **A:**  Complete blood count (CBC) with platelet count and anti-Xa levels,
      especially in pregnancy.
    a: >-
      A:**  Complete blood count (CBC) with platelet count and anti-Xa levels,
      especially in pregnancy.
  - q: >-
      What is the difference between Certoparin and unfractionated heparin?**


      **A:** Certoparin is a low-molecular-weight heparin (LMWH), with a more
      predictable anticoagulant response and a longer half-life, allowing for
      once or twice-daily dosing. It predominantly inhibits factor Xa, whereas
      unfractionated heparin inhibits both factor Xa and thrombin.
    a: >-
      A:** Certoparin is a low-molecular-weight heparin (LMWH), with a more
      predictable anticoagulant response and a longer half-life, allowing for
      once or twice-daily dosing. It predominantly inhibits factor Xa, whereas
      unfractionated heparin inhibits both factor Xa and thrombin.
  - q: >-
      How should Certoparin be dosed in renal impairment?**


      **A:** The dose needs to be reduced based on the degree of impairment. Use
      0.75mg/kg dosing for patients with moderate or severe renal impairment. 
      Consult the detailed dosage guidelines for specific recommendations.
    a: >-
      A:** The dose needs to be reduced based on the degree of impairment. Use
      0.75mg/kg dosing for patients with moderate or severe renal impairment. 
      Consult the detailed dosage guidelines for specific recommendations.
---
## **Usage**

- Certoparin is prescribed for the prevention and treatment of venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). It is also used in other medical settings where there is a risk of blood clot formation such as post-surgery and in acutely ill hospitalized medical patients.  
- **Pharmacological Classification:** Anticoagulant, specifically a low-molecular-weight heparin (LMWH).
- **Mechanism of Action:** Certoparin primarily potentiates the activity of antithrombin III. Antithrombin III inhibits coagulation factor Xa and thrombin (factor IIa). Certoparin has a higher ratio of activity against factor Xa compared to thrombin and therefore, is more specific than unfractionated heparin in its mechanism.

## **Alternate Names**

- Certoparin sodium
- Sandoparin®
- Embolex®


## **How It Works**

- **Pharmacodynamics:** Certoparin, like other LMWHs, primarily inhibits factor Xa, preventing clot formation. It also inhibits thrombin to a lesser extent, acting on both the coagulation initiation and propagation phases.
- **Pharmacokinetics:** Administered subcutaneously, certoparin reaches peak plasma concentration in approximately 4 to 5 hours. It has a half-life of around 4 to 5 hours.
- **Mode of Action:** Certoparin binds to antithrombin III, enhancing its ability to inhibit factor Xa and, to a lesser extent, thrombin.  This reduces the conversion of prothrombin to thrombin and fibrinogen to fibrin, thereby inhibiting clot formation. 
- **Elimination Pathways:** Primarily renal excretion. Dose adjustments are needed in patients with renal impairment.

## **Dosage**

### **Standard Dosage**

#### **Adults:**

- **Prophylaxis of VTE:** 3,000 IU aXa once daily or 30 mg once daily subcutaneously for 7 to 10 days post-surgery. In acutely ill medical patients, it is given at 3,000 IU anti-Xa of certoparin once daily.
- **Treatment of DVT:** 8,000 IU aXa twice daily subcutaneously, or 1 mg/kg/12 hours for up to 14 days.
- **Treatment of established DVT and PE:** 8,000 IU twice daily subcutaneously, or 1 mg/kg every 12 hours.

#### **Children:**

- Limited data are available for pediatric dosing. Safety and efficacy have not been firmly established.

#### **Special Cases:**

- **Elderly Patients:**  Caution is advised in elderly patients. Dose adjustment may be necessary due to age-related decline in renal function. For those over 75, avoid an initial IV bolus and limit initial subcutaneous doses to 75mg. Use 0.75mg/kg dosing for all subsequent subcutaneous doses.
- **Patients with Renal Impairment:** Dose reduction is needed for patients with moderate to severe renal impairment. Use 0.75mg/kg once daily.
- **Patients with Hepatic Dysfunction:** Use with caution. No specific dosage guidelines exist, but monitoring for bleeding is essential. The drug is contraindicated in patients with severe hepatic dysfunction.
- **Patients with Comorbid Conditions:** Careful consideration is needed when co-prescribing with other drugs that increase the risk of bleeding (such as NSAIDs and aspirin) as dose adjustments may be required. Close patient monitoring should be performed.


### **Clinical Use Cases**

- **Intubation, Surgical Procedures, Mechanical Ventilation, ICU Use:** 3000 IU anti-Xa once daily for 10 ± 2 days.
- **Emergency Situations:**  Dosage will depend on the specific clinical scenario.


### **Dosage Adjustments:**

- Monitor renal function closely and adjust the dose accordingly.
- Monitor for signs and symptoms of bleeding.


## **Side Effects**

### **Common Side Effects:**

- Bleeding or bruising at the injection site
- Minor bleeding (e.g., nosebleeds, gum bleeding)

### **Rare but Serious Side Effects:**

- Major bleeding (e.g., gastrointestinal bleeding, intracranial hemorrhage)
- Thrombocytopenia (low platelet count)
- Allergic reactions (e.g., rash, itching, swelling)

### **Long-Term Effects:**

- Osteoporosis (with long-term use)
- Alopecia (hair loss)


### **Adverse Drug Reactions (ADR):**

- Spinal or epidural hematoma (in patients receiving neuraxial anesthesia or spinal puncture)
- Heparin-induced thrombocytopenia (HIT)


## **Contraindications**

- Active major bleeding
- Severe thrombocytopenia
- Hypersensitivity to certoparin or heparin
- Bacterial endocarditis
- Severe uncontrolled hypertension

## **Drug Interactions**

- Other anticoagulants (e.g., warfarin, DOACs)
- Antiplatelet agents (e.g., aspirin, clopidogrel)
- NSAIDs 
- Certain medications that can increase potassium levels (e.g., ACE inhibitors, ARBs)
- Alcohol (may increase risk of bleeding)

## **Pregnancy and Breastfeeding**

- Certoparin does not cross the placenta and has been used in pregnant women at risk for VTE. Data suggest it is safe and effective for VTE prophylaxis in pregnant women. Monitor coagulation parameters.
- Certoparin is not excreted in breast milk in clinically significant amounts. It is generally considered safe to use while breastfeeding. 


## **Drug Profile Summary**

- **Mechanism of Action:**  Primarily inhibits factor Xa via potentiation of antithrombin III. 
- **Side Effects:** Bleeding, bruising, thrombocytopenia, allergic reactions, osteoporosis, alopecia.
- **Contraindications:** Active major bleeding, severe thrombocytopenia, hypersensitivity.
- **Drug Interactions:** Other anticoagulants, antiplatelet agents, NSAIDs.
- **Pregnancy & Breastfeeding:** Generally safe, does not cross the placenta, not excreted in breast milk in significant amounts.
- **Dosage:** Varies depending on indication and patient characteristics (see dosage section above).
- **Monitoring Parameters:**  Complete blood count (CBC), including platelet count, and  anti-factor Xa levels.

## **Popular Combinations:**

- Often used in sequence with warfarin, initially with certoparin then transitioning to warfarin.

## **Precautions:**

- **General Precautions:** Monitor for signs of bleeding, assess renal function, and co-prescribed medications.
- **Specific Populations:** Caution in elderly patients and patients with renal or hepatic impairment. Monitor pregnant women's coagulation parameters.
- **Lifestyle Considerations:** Avoid alcohol and other drugs that increase bleeding risk.


## **FAQs (Frequently Asked Questions)**

### **Q1: What is the recommended dosage for Certoparin?**

**A:**  The dosage varies according to the clinical indication. See detailed dosing information above.

### **Q2: How is Certoparin administered?**

**A:** Subcutaneous injection.

### **Q3: What are the key side effects to watch for?**

**A:**  Bleeding, bruising, thrombocytopenia, allergic reactions.

### **Q4: What are the contraindications to Certoparin use?**

**A:** Active major bleeding, severe thrombocytopenia, hypersensitivity to certoparin or heparin.

### **Q5: Can Certoparin be used in pregnancy?**

**A:** Yes, it has been shown to be safe and effective in preventing VTE during pregnancy. It does not cross the placenta. Monitor coagulation parameters and pregnancy complications.

### **Q6: Is Certoparin safe during breastfeeding?**

**A:**  Yes, it is not secreted in clinically significant amounts into breast milk.

### **Q7: How does Certoparin interact with other anticoagulants?**

**A:**  Increases the risk of bleeding.  Close monitoring is needed when used concomitantly.

### **Q8: What should be monitored in patients receiving Certoparin?**

**A:**  Complete blood count (CBC) with platelet count and anti-Xa levels, especially in pregnancy.

### **Q9: What is the difference between Certoparin and unfractionated heparin?**

**A:** Certoparin is a low-molecular-weight heparin (LMWH), with a more predictable anticoagulant response and a longer half-life, allowing for once or twice-daily dosing. It predominantly inhibits factor Xa, whereas unfractionated heparin inhibits both factor Xa and thrombin.

### **Q10: How should Certoparin be dosed in renal impairment?**

**A:** The dose needs to be reduced based on the degree of impairment. Use 0.75mg/kg dosing for patients with moderate or severe renal impairment.  Consult the detailed dosage guidelines for specific recommendations.
